Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check out the treatment roadmap for the next 15 months. Page 14
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Conversion Labs, Inc. (OTCQB: CVLB), a direct-to-consumer telemedicine and wellness company, has appointed noted expert in internal medicine, Dr. Jeff Toll, to its medical advisory board.
As an industry thought-leader on holistic health and preventative care, Dr. Toll has joined the board to help guide the development and expand awareness of Conversion Labs’ growing portfolio of telemedicine brands, including Rex MD, Shapiro MD and SOS Rx.
Dr. Toll brings to Conversion Labs an extensive record of medical experience, research and accomplishment. Board certified in internal medicine, Dr. Toll completed his medical training at Cedars-Sinai Medical Center in Los Angeles, which ranks among the top 10 hospitals in the country. He earned his bachelor’s degree from the University of Southern California and medical doctorate from Thomas Jefferson University in Philadelphia. A popular influencer on social media, Dr. Toll has more than 38,000 followers on his Instagram.
“We look forward to benefiting from Dr. Toll’s real-world clinical experience and his deep knowledge and experience with innovative and novel health and wellness products,” commented Justin Schreiber, CEO of Conversion Labs. “Our telemedicine platform improves access to medical treatment, prescription medications and innovative over-the-counter products. Endorsements and support from influential and opinion leading physicians like Dr. Toll help us to fulfill our mission of using this platform to improve the quality of care.”
Dr. Toll’s Los Angeles-based private practice is focused on delivering integrated preventive care. His holistic approach provides highly personalized care that caters to each patient’s whole health, including mind, body and soul. Dr. Toll is also a volunteer faculty member at Cedars-Sinai Internal Medicine Residency, teaching interns, residents and UCLA medical students. His medical research has been published in the areas of medical genetics, cancer and addiction.
“In a post-COVID-19 world, telemedicine is one of the fastest growing segments of healthcare, and it will fundamentally change how clinicians like myself treat patients forever,” commented Dr. Toll. “Telemedicine enables doctors to do very positive things for patients, including increase quality of care and access to care.
“I joined Conversion Labs’ telemedicine advisory board because I was impressed with the nationwide telemedicine platform they built over the past year and its strong commercial traction within just six months from launch. I plan to utilize my knowledge and experience in concierge medicine and clinical research to help Conversion Labs further grow their portfolio of telemedicine brands and maximize the quality of care provided to each Conversion Labs customer.”
The company launched Rex MD as its first telemedicine brand last December. Rex MD has been initially focused on treating erectile dysfunction, with the global market expected to exceed $2.9 billion by 2023. Rex MD plans to soon offer treatments for longevity, strength and endurance, hair loss, skin care and other indications.
Conversion Labs recently received FDA 510(k) clearance for its new hair regrowth product, the Shapiro MD Laser Hair Restoration Device. The device addresses the global hair restoration market that is growing at a 4.6% compounded annual growth rate and expected to exceed $12 billion by 2026.
The company also recently reported that its overall sales jumped 274% in May to a record $3.2 million. The May results indicate an annualized net revenue run-rate of more than $38 million in 2020 versus total net revenues of $12.5 million in 2019. This rapid growth is being driven by a combination of well-designed and effective products and a major consumer shift to eCommerce and telemedicine following the outbreak of COVID-19.
https://ir.conversionlabs.com/CVLB%20Investor%20Presentation%20October%202020.pdf
Takeaways:
Veritas MD platform launching expected for this month.
10% increase in customer count, month over month. September presentation was 200,000. Page 8
Both Telemedicine and the SaaS segments in an uptrend in Q3. Page 9.
I don’t think so. I will sell a house for sure to buy more then.
Did you forget about the Price to Sales valuation??? Which is currently below 4 and the peer average is above 20.
Uplisting to the Nasdaq? Record Q3, Q2, Q1, Record FY2020? Veritas and everything else?
The RSS was imminent because the price need was $4.00 and NOT $2.00.
And I like the fact that we went higher to get the institutional investors onboard right away. The wise ones would want to get onboard before the uplisting to the Nasdaq.
The RSS combined with an Equity Raise (close to market price and fixes the balance sheet) and record Q3 posted will send the stock flying to proper valuation.
I have the strong feeling that this was the perfect timing for doing the imminent reverse split. The company will be much appreciated at these levels that it was being in the penny land.
One huge step away from the POS penny land. I am actually very glad about all this.
You will be owning A REAL STOCK SOON and with HUGE potential. 65 / 35 chance or better of becoming a Billion $$$ company.
There has been past developments such as RECORD FY2018 & FY2019, Q1 Q2, and now Q3. Definitely a RECORD FY2020.
The strong growth trend ALONE supports your investment in this company. Specially at this ultra low valuations.
Financing fixes the balance sheet (which is required by the NASDAQ) and the upcoming RECORD Q3 will tell the rest of the story, Institutions are very wellcome because they can now buy the stock. And once a couple do it, the rest will follow.
Period. End of message.
$AYTU Q3 REPORT
Net cash used in operating activities.............(20,609,198) +100% INCREASE AGAIN
GL WITH THIS $$$ LOSER
AYTU Q results:
Total revenue........
8,156,173 ...............2,377,792
Total operating expenses..................
12,949,616 ..................6,676,430
JUST HORRIBLE
[b[color=red]]A TOTAL DISASTER AHEAD[/color]
IMMINENT COLLAPSE IN STOCK PRICES
Many COVID TEST COMPANIES DOING FAR BETTER
$AYTU It's NOT a GOLDEN investment and it's OK with me. If the Biolidics test hit the market right NOW, $AYTU will sell everything they can get their hands on to POC locations but It LOOKS more like a P&D with the constant posting here about that chinese trash the company was or is selling for the past few months. The POC market is big but has it's limits.
There is NO an AUTHORITY on this subject close by
The company to make LOTS of MONEY will be the one tho get the RAPID test FDA EUA approval for IN_HOUSE USE. $AYTU might get it but I BELIVE IS A LONG SHOT from seeing the performance numbers of other competitors.
If AYTU makes money from the Singapore products the stock price has to go up.
Questions and ONLY Questions:
Has it already been priced in? No-one seemed to even know what the shares outstanding were when I first posted here, so how can you answer that question.
What the current AYTU price to sale ratio.
What's the expected one once you manage to land the product on the market? Do you have any company you can compare to?
Any reference to compare from?
How much is the Healight is going into the current SP? Is that the best therapeutic product that can be developed? VERY INVASIVE.. Does it work? Probably.
Very simple question....How far into the LUNGS can it reach? How many times does it have to be used?
Why NOT a product that can stop it from getting to the lungs. Why wait until it gets complicated?
Isn't heated air to just above 56 degrees C a better solution? Someone will follow this approach and IT IS NOT AS INVASIVE
Have you heard of the "COLD ARREST" therapy? It's only 30 plus YEARS old and it works
So I PERSONALLY have LOTS of doubts, BUT THAT'S ME. I am NOT an expert nor a SHORT seller.
Just an interested investor searching for the best options out there like many more.
RESPECT OF OPINIONS IS PARAMOUNT
AYTU AYTU AYTU Aytu Bioscience In. Ticker AYTU AYTU AYTU
THIS POST IS ALL ABOU THE COMPANY TICKER AYTU,PAST CURRENT AND FUTURE BUSINESS OPPORTUNITIES.
$AYTU $AYTU PRODUCT IS NOT GOLDEN.
I could show you a dozen rapid tests with better quality, better accuracy numbers and bigger production facilities. The information is all out there. Look it up.
My honest bet for $AYTU IN-House FDA EUA APPROVAL is about a 20-30% chance. VERY POOR.
Be content if you can move the BIOLOGICS tests as POC tests.
$AYTU $AYTU PRODUCT IS NOT GOLDEN.
AYTU AYTU AYTU Aytu Bioscience In. Ticker AYTU AYTU AYTU
THIS POST IS ALL ABOU THE COMPANY TICKER AYTU,PAST CURRENT AND FUTURE BUSINESS OPPORTUNITIES.
$AYTU. Will NOT be able to sell those Chinese tests any longer. They are substandard, poor or trash products. And that's just my honest opinion.
AYTU/ BIOLIDICS
It is NOT an article. It's only information.
Things (accuracy parameters) changed for the FDA flexibility. This is VERY NORMAL given the time elapsed and the number of NEW entrants.
DON'T SHOOT THE MESSENGER.
https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy
I posted several links in the past couple of days warning about all this.
I believe the Biolidics test is within the desired accuracy range and that's why the company switched and got the exclusivity agreement. So it's only time until the products arrive to the market.
JMHO
FDA tightens rules on COVID-19 tests aimed at corralling bad actors
https://seekingalpha.com/news/3568338-fda-tightens-rules-on-covidminus-19-tests-aimed-corralling-bad-actors
One more FDA EUA approved.
SARS-CoV-2
ELISA test systems from EUROIMMUN
https://www.coronavirus-diagnostics.com/antibody-detection-tests-for-covid-19.html
NOT APPROVED YET
https://www.coronavirus-diagnostics.com/pcr-test-for-the-detection-of-sars-cov-2.html
Insight into FDA’s Revised Policy on Antibody Tests: Prioritizing Access and Accuracy
https://www.fda.gov/news-events/fda-voices/insight-fdas-revised-policy-antibody-tests-prioritizing-access-and-accuracy
Thermo Fisher Scientific commits to rapidly expanding testing capacity from 5 to 10 million tests per week
http://thermofisher.mediaroom.com/feature-stories?item=40
Fast, portable tests come online to curb coronavirus pandemic
https://www.nature.com/articles/d41587-020-00010-2
A CHART INCLUDED
RE: About $ROCHE AYTU Competition
https://www.selectscience.net/industry-news/roche-covid-19-antibody-test-wins-fda-approval-for-emergency-use?artID=51414
https://diagnostics.roche.com/global/en/products/params/elecsys-anti-sars-cov-2.html
Elecsys® Anti-SARS-CoV-2 is an immunoassay for the in vitro qualitative detection of antibodies (including IgG) to SARS-CoV-2 in human serum and plasma. The test is intended as an aid in the determination of the immune reaction to SARS-CoV-2.
The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analysers. The assay uses a recombinant protein representing the nucleocapsid (N) antigen for the determination of antibodies against SARS-CoV-2.
Elecsys® Anti-SARS-CoV-2 Factsheet
Also, just to be clear:
The market is too big for Abbott and ROCHE put together.
I REPEAT.
The market s too big for ABBOTT and ROCHE put together.
LOL So much enthusiasm....
RE: AYTU Market Competition
https://sports.yahoo.com/roche-gets-emergency-fda-approval-144855994.html
(Not in the FDA list yet)
Switzerland’s Roche Holding AG (RHHBY) announced on Sunday that its antibody test, which seeks to determine if an individual has been infected with the coronavirus, has received emergency approval by the U.S. Food and Drug Administration (FDA).
“We are now able to deliver a high-quality antibody test in high quantities, so we can support healthcare systems around the world with an important tool to better manage the COVID-19 health crisis,” said Severin Schwan, CEO of the Roche Group. ”I am in particular pleased about the high specificity and sensitivity of our test, which is crucial to support health care systems around the world with a reliable tool to better manage the COVID-19 health crisis.”
The Swiss drugmaker said it has already started shipping the antibody tests to leading laboratories around the world and will ramp up production capacity to provide “high double-digit millions” of tests in May to healthcare systems in countries accepting the European CE regulatory mark as well as the U.S.
The antibody test, which has a specificity greater than 99.8% and 100% sensitivity aims to help assess patients’ immune response to the virus, the drugmaker said.
This looks like a Molecular Test, Not an AB one. Need to check the list .
I don't know about ROCHE but ABBOTT's test requires a lab and a machine to get the results. They could get a Rapid Test too but I haven't seen any from them yet.
And as a matter of fact I haven't seen a ROCHE test (Rapid) EUA approved or in the market. It could end up being a lab test which requires a machine.
IMO Rapid Tests CLOSE to 95% accuracy, at least in the IgG part (longer term) will sell. If it's a double test with the IgM accuracy above 90 will be considered good enough.
And the REAL WINNERS will be the ones getting the Rapid In-House Tests EUA approved. Those companies will make some serious CASH in the Short term. That's why the production capacity is so important. You need HQ, good accuracy BUT a production capacity in excess of 500K a day because the window could be of several months only.
There is a tremendous NEED for all the AB Tests ready to roll. Any body close to these parameters will sell everything they have available.
By the way, which test are you referring to here:
“We're currently manufacturing 50,000 tests per day, plan to increase ID NOW manufacturing capacity to 2 million tests a month by June and are working to expand beyond that.”
The chinese or the Biolidics one?
TIA
AYTU. A reference you can use as to what's out there in the market.
COVID-19 Testing Project
https://covidtestingproject.org/index.html
On the company web page the numbers are better (closer to what the FDA is looking for) and also the time for the results. So I'm guessing the company is moving forward with the new tests from Biolidics.
In reality these are serology antibody tests and you want from them is to know if you have been exposed to the virus so the IgG accuracy, which is the longer term AB indicator, is the one that has to be around 95% or better if possible.
https://aytubio.com/covid-19/
AYTU Rapid test. I hope the Biolidics test numbers are better. This "Zhejiang Orient Gene Biotech, Co., Ltd. COVID-19 IgG/IgM Rapid Test Cassette" is far from being the best (Gold Standard) out there.
Sorry, there are tests in the market that were validated with over 400, and 900 people with far better numbers. The best test have both sensitivity and specificity validations above 90%. Specificity should be 100% and sensitivity as close to 95% as possible.
Check the real results below.
-------------------------------------------
https://www.tandfonline.com/doi/full/10.1080/20008686.2020.1754538
IgM and IgGreactivities in PCR-confirmed COVID-19 patients
Altogether 20 of 29 (69%) samples from PCR-confirmed COVID-19 patients tested IgM positive and 27 tested (93.1%) IgG positive (Tables 1 and 2). When the patients were grouped into two groups depending on the time between onset of disease and testing, seven out of ten patients in the first group (9–17 days) and 13/19 patients in the second group (18–29 days) tested IgM positive. Nine out of ten patients in the first group (9–17 days) and 18/19 patients in the second group (18–29 days) tested IgG positive (Figure 1). There was no statistical difference between the two groups for neither IgM or IgG seropositivity. All samples that were IgM positive were also IgG positive.
Discussion
In this study we evaluated a commercial rapid test for detection of SARS-CoV-2-specific IgM and IgG. For the evaluation, samples from COVID-19 cases, obtained during disease or convalescence and previously confirmed by PCR, were used as ‘true positives’. This means that in the PCR-positive cases for which antibodies may not yet had time to develop, or in potential cases with immune defects, it is possible that the negative IgM or IgG results were in fact true negatives. If this was the case for one or more of the included patients, the actual sensitivities should be higher, i.e. when evaluated only on samples known to contain detectable levels of SARS-CoV-2-specific IgM and/or IgG. For a more optimal evaluation of the assay sensitivity, a gold standard for SARS-CoV-2-specific antibodies would have been needed. This is, however, unfortunately not available to date.
According to the manufacturer, the specificity has been evaluated on 14 PCR-negative samples and was found to be 100% for both IgM and IgG, while the sensitivity evaluated on COVID-19 cases was calculated at 87.9% for IgM and 97.2% for IgG. [color=red]The results by Li et al. [11] indicated an overall testing sensitivity of 88.7% and 90.6% specificity. Our results showed a lower sensitivity for IgM, a similar sensitivity for IgG, and specificities in between the results of the two evaluations.[/color]
A recent study on three Chinese COVID-19 cases found that seroconversions occurred between 7 and 12 days after the onset of symptoms [12]. However, larger studies on the detailed kinetics of the antibody responses (e.g. IgA, IgM, IgG, neutralizing antibodies) are now urgently needed for a better understanding of the dynamics of the immune response during COVID-19. The results of our study showed detectable IgM and IgG in some patients at day 9, while in other patients the seroconversion seems to occur later. The impact of early or late seroconversion on the case severity is not known, and must now be explored. Interestingly, there were no IgM positives that were not IgG positive. Generally, IgM is produced first, and later there is a switch towards IgG production [13], but studies on SARS-CoV suggest that IgM and IgG often develop around the same time [14,15]. Our results are in line with this (Figure 1), but more detailed studies on long-term sequential samples from patients are now needed. It may be worth looking into whether this is a problem with the test, or a constant finding within the immune response to SARS-CoV-2.
There were no false IgM positive samples, indicating a very high specificity of the test. One false positive IgG result was observed for one healthy adult blood donor. This sample was re-tested and the result was consistent, indicating a cross-reaction to another coronavirus. Serological cross-reactions have earlier been observed between SARS-CoV and SARS-CoV-2 [16]. There are other human coronaviruses (NL63, OC43, 229E, and HKU1) that are globally endemic or epidemic [17], and it may be possible that this reaction represented a cross-reaction due to a previous infection with one of those. Human CoV NL63 has been shown to use the same receptor, angiotensin-converting enzyme 2 (ACE2), as SARS-CoV and SARS-CoV-2 [18], which may indicate potential cross-reactive epitopes. How common the CoVs are as causative agents for ‘common colds’ is not known in detail, but there has been estimates that up to 20% of cases could be caused by CoVs [19].
The specificity and sensitivity for IgG detection of the rapid test evaluated here is well in line with those of a recently reported enzyme-linked immunosorbent assay (ELISA), which had a specificity and a sensitivity of 97.5% [20].
While this study showed a satisfactory performance of the rapid test, it is limited by being compared only to clinical cases and PCR-positivity, and as a next step, it is necessary to compare this assay to other serological tests. [color=red]In contrast to Li et al. [11], we found less indications for using this test for clinical diagnosis. [/color]Nevertheless, it might contribute to detecting potential asymptomatic infections as well as getting a notion of the magnitude of the spread in different geographical areas, which might be a key to taking the appropriate decisions and policies forward. The high negative predictive value indicates that the rapid test will be useful for detecting past infections and possible immunity, which may be crucial for restoring social functions after lockdown.
Thanks and I agree with you here. 60.59M shares
I check the following list every day:
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd
And the following is the list of awaiting companies in different stages of the process.
https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-diagnostic-testing-sars-cov-2
Need to look under:
What Laboratories and Manufacturers are Offering Tests for COVID-19?
Q: What serology tests are being offered under the policy outlined in Section IV.D of the Policy for Diagnostic Tests for Coronavirus Disease-2019? (Updated 4/30)
and
Manufacturers that have notified FDA that they have validated and are offering serology tests as set forth in Section IV.D:
Biolidics Limited 2019-nCoV IgG/IgM Detection Kit (Colloidal Gold) Not FDA Authorized
The kit is on the list awaiting approval. 170 manufacturers and growing. And that's why HQ is important.
10 companies for serology tests already approved but very few practical ones with great sensitivity and specificity numbers. Most are complicated tests which require a machine or device to read the results. Some are just labs.
There are better ones in the market waiting for approval.
$AYTU. Include the Total Shares Outstanding. It's missing!
Things to consider when making the projection:
1. Biolidicts' past experience. How many Quality of products.
2. Output capacity. 250K, 500K or more a day? How many more products share this capacity?
3. Product fact sheet and validation studies with numbers such as:
IgM & IgG Sensitivity & Specificity. Does it requires a special equipment?
How many people or subjects were involved.
Has this product/validation been presented to the FDA? This is a fairly NEW deal. The fact that AYTU has good FDA experience helps in this case BUT the clock is ticking.
Has the EUA approval process been started? For POC and In House?
There are other things but these should do for now.
Very important: What's the typical SPLIT in a deal like this one? How much would AYTU be making as net revenue per kit sold?
Note: I like the fact that Biolidicts is based in Singapore. Normally HQ products and there should be NO problems exporting.
OK, I see your concern.
I am following but what I am talking about is REAL projections trying to leave the speculation out for at least the next 12 months. There are some interesting things happening with AYTU I admit but it's important to keep the boots on the ground.
What's needed is more fundamental information. That's what makes a stock move decisively. Unless you are a 100% trader, then is OK and I understand.
RE: AYTU. I believe you are wrong
My Charles Schwab platform for AYTU says: Nasdaq 58.xM
The last Q report says:
Weighted average number of common shares outstanding: 17,538,148
And
Check the video here @ min: 00.38 It says 60.59M
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155379085
The NASDAQ webpage says: Market Cap 145,523,459 ( / 1.60 = 90.95M Shares
I have also seen 98.9M shares in other places, more than once.
-------------------------------------------------
So NO ONE on this board knows how much they are paying for this stock.
NO ONE knows the real Market Cap nor the PRICE TO SALES (P/S) RATIO
How can you be invested in a stock that you have NO IDEA what the valuation is at the moment. Which is very important to know to understand if AYTU is being fairly valued @ SP = $1.60 compared to industry peers.
Does anybody knows what's the SALES number for the past 4 quarters?
Or the future Sales projection (Estimated) for the next 4?
When you answer these questions and after considering the rest (management, IP, products, plans & financials) then you will be far more confident if investing or NOT in AYTU BioScience.
The REST IS (Mostly) NOISE
Have a good weekend
Very simple question: Does anybody knows the share structure of the company?
How many shares outstanding? Total common.
Thanks
jefra1965 Friday, 05/01/20 08:55:04 AM
Re: None 0
Post # of 16079
Good morning to the board. I have been taking a look into the company but I have not been able to figure out the REAL Shares Outstanding Count to date. Could someone help me with this information.
I am getting different numbers from different sources. 10.2M Preferred Stocks and 20.73M Common from the last Q report. But my platform says 68M and other places indicate 96M shares. Very confusing.
What's the relation to calculate the total.
TIA
There is NO exclusivity so it has to be higher. 40-50% my guess. It could be even higher since Ayto has to pay for getting them approved.
jefra1965 Friday, 05/01/20 08:55:04 AM
Re: None 0
Post # of 15990
RE: AYTU Bioscience
Good morning to the board. I have been taking a look into the company but I have not been able to figure out the REAL Shares Outstanding Count to date. Could someone help me with this information.
I am getting different numbers from different sources. 10.2M Preferred Stocks and 20.73M Common from the last Q report. But my platform says 68M and other places indicate 96M shares. Very confusing.
What's the relation to calculate the total.
TIA
Biolidics retains the right to sell the Covid-19 test kits directly to certain clinical partners in the US.
Under the terms of the agreement, Aytu must purchase from the medtech firm an initial 500,000 Covid-19 test kits within one business day from the date of the agreement.
Thereafter, within the first three months, Aytu is required to buy at least 1.25 million of the test kits in order to remain as the exclusive distributor. All third-party orders arising from Biolidics' own referrals and sales will not be included in this minimum exclusive commitment.
During the term of the agreement, Aytu will also pay for and lead the clinical trials' processes, to complete and obtain regulatory clearance from the US Food and Drug Administration (FDA) for the test kits under Section 510(k) of the US Federal Food, Drug and Cosmetic Act.
If Aytu completes this clearance, the US company will maintain exclusivity for the remainder of the term of the agreement.
Completing the clearance allows Biolidics to sell its Covid-19 test kits in the US under Section 510(k). This will be in addition to the completed Section IV.D of the FDA's guidance document Policy for Diagnostic Tests for Coronavirus Diseases-2019 during the Public Health Emergency, which was implemented to help rapidly expand testing capacity during the pandemic, and may be terminated after the period of the public health emergency.
Biolidics said the Aytu distribution deal is likely to contribute positively to its revenue for the current financial year ending Dec 31, 2020.
"However, the company is unable to quantify the financial impact as there are no minimum purchase quantities beyond the first three months of the agreement," Biolidics added.
https://www.straitstimes.com/business/companies-markets/biolidics-inks-us-distribution-deal-for-its-covid-19-test-kits
Thanks and good luck
I understand that these tests are selling for $110-$115. Is the company keeping $25 a piece? Is this your estimate. I don't see any numbers $$$ in the PRs.
Also, AytuBio only represents the Chinese Producer in the US like many other companies. AYTU is not the developer of the product. So how is that revenue split among them. How much is AYTU really keeping after paying the Chinese their product? $10...$12.5 or $15?